Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
1,785.10
-19.00 (-1.05%)
Oct 7, 2026, 1:10 PM IST
NSE:SUNPHARMA Revenue
Sun Pharmaceutical Industries had revenue of 153.00B INR in the quarter ending June 30, 2026, with 10.46% growth. This brings the company's revenue in the last twelve months to 599.11B, up 11.41% year-over-year. In the fiscal year ending March 31, 2026, Sun Pharmaceutical Industries had annual revenue of 584.62B with 11.19% growth.
Revenue (ttm)
599.11B
Revenue Growth
+11.41%
P/S Ratio
7.23
Revenue / Employee
12.75M
Employees
47,000
Market Cap
4.28T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 584.62B | 58.84B | 11.19% |
| Mar 31, 2025 | 525.78B | 40.82B | 8.42% |
| Mar 31, 2024 | 484.97B | 46.11B | 10.51% |
| Mar 31, 2023 | 438.86B | 52.31B | 13.53% |
| Mar 31, 2022 | 386.54B | 51.56B | 15.39% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 349.35B |
| Zydus Lifesciences | 285.92B |
| Cipla | 280.68B |
| Glenmark Pharmaceuticals | 177.37B |
| Alkem Laboratories | 150.81B |
| Mankind Pharma | 147.38B |
| Divi's Laboratories | 112.30B |
| Ipca Laboratories | 101.26B |
Sun Pharmaceutical Industries News
- 5 days ago - Sun Pharma Reports Two-Year LEQSELVI Data In Severe Alopecia Areata - Nasdaq
- 6 days ago - Mayne Pharma, Sun Pharma Settle IMVEXXY Patent Case, Generic Entry Set For 2032 - Nasdaq
- 7 days ago - Mayne Pharma Settles IMVEXXY Patent Litigation With Sun Pharma - Nasdaq
- 7 days ago - India's Sun Pharma plans $1 billion local debt sale for loan takeout, sources say - Reuters
- 12 days ago - Sun Pharma Launches Osmotic Delivery Formulation Of Methylphenidate In Canada - Nasdaq
- 12 days ago - Sun Pharma Launches Taro-Methylphenidate ER, Generic Alternative To Concerta - Nasdaq
- 13 days ago - Sun Pharma Backs The First Standardized U.S. Treatment Recommendations For Severe Alopecia Areata - Nasdaq
- 5 weeks ago - Cipher Pharmaceuticals Secures Court Confirmation Of Arbitration Award - Nasdaq